Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0001610717-24-000433 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-22 | 2024-08-20 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | +6,875 | 110.1K | +7% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Ogden Christopher | CFO | S - Sale+OE | $1.23 | -1,984 | 108.1K | -2% | -$2,440 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | -6,875 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-20 | M | A | 6,875 | $0.00 | 110,061 | D | — | — | (F2) Includes 77,810 restricted stock units. |
| 2 | Common | Common Stock | 2024-08-20 | S | D | 1,984 | $1.23 | 108,077 | D | — | — | (F2) Includes 77,810 restricted stock units. |
| 3 | Derivative | Performance Stock Units (PSUs) | 2024-08-20 | M | D | 6,875 | $0.00 | 0 | D | — · — to — | 6,875 Common Stock | (F4) Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone. |